acquired
Stage
2016
Founded
4
Investors
About
ImCheck Therapeutics develops immunotherapeutic antibodies targeting butyrophilin and related checkpoint molecules to treat cancer, infectious diseases, and autoimmune disorders.
Explore ImCheck Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.